Literature DB >> 33468661

Multiple domain interfaces mediate SARM1 autoinhibition.

Chen Shen1,2, Mihir Vohra3, Pengfei Zhang1,2, Xianrong Mao3, Matthew D Figley4, Jian Zhu3, Yo Sasaki3, Hao Wu5,2, Aaron DiAntonio6,7, Jeffrey Milbrandt8,7.   

Abstract

Axon degeneration is an active program of self-destruction mediated by the protein SARM1. In healthy neurons, SARM1 is autoinhibited and, upon injury autoinhibition is relieved, activating the SARM1 enzyme to deplete NAD+ and induce axon degeneration. SARM1 forms a homomultimeric octamer with each monomer composed of an N-terminal autoinhibitory ARM domain, tandem SAM domains that mediate multimerization, and a C-terminal TIR domain encoding the NADase enzyme. Here we discovered multiple intramolecular and intermolecular domain interfaces required for SARM1 autoinhibition using peptide mapping and cryo-electron microscopy (cryo-EM). We identified a candidate autoinhibitory region by screening a panel of peptides derived from the SARM1 ARM domain, identifying a peptide mediating high-affinity inhibition of the SARM1 NADase. Mutation of residues in full-length SARM1 within the region encompassed by the peptide led to loss of autoinhibition, rendering SARM1 constitutively active and inducing spontaneous NAD+ and axon loss. The cryo-EM structure of SARM1 revealed 1) a compact autoinhibited SARM1 octamer in which the TIR domains are isolated and prevented from oligomerization and enzymatic activation and 2) multiple candidate autoinhibitory interfaces among the domains. Mutational analysis demonstrated that five distinct interfaces are required for autoinhibition, including intramolecular and intermolecular ARM-SAM interfaces, an intermolecular ARM-ARM interface, and two ARM-TIR interfaces formed between a single TIR and two distinct ARM domains. These autoinhibitory regions are not redundant, as point mutants in each led to constitutively active SARM1. These studies define the structural basis for SARM1 autoinhibition and may enable the development of SARM1 inhibitors that stabilize the autoinhibited state.

Entities:  

Keywords:  NMN; axonopathy; metabolism; neurodegeneration; neuropathy

Mesh:

Substances:

Year:  2021        PMID: 33468661      PMCID: PMC7848697          DOI: 10.1073/pnas.2023151118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  44 in total

1.  NMN Deamidase Delays Wallerian Degeneration and Rescues Axonal Defects Caused by NMNAT2 Deficiency In Vivo.

Authors:  Michele Di Stefano; Andrea Loreto; Giuseppe Orsomando; Valerio Mori; Federica Zamporlini; Richard P Hulse; Jamie Webster; Lucy F Donaldson; Martin Gering; Nadia Raffaelli; Michael P Coleman; Jonathan Gilley; Laura Conforti
Journal:  Curr Biol       Date:  2017-03-02       Impact factor: 10.834

2.  The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration.

Authors:  Kow Essuman; Daniel W Summers; Yo Sasaki; Xianrong Mao; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Neuron       Date:  2017-03-22       Impact factor: 17.173

Review 3.  The many faces and functions of β-catenin.

Authors:  Tomas Valenta; George Hausmann; Konrad Basler
Journal:  EMBO J       Date:  2012-05-22       Impact factor: 11.598

4.  Structural Evidence for an Octameric Ring Arrangement of SARM1.

Authors:  Michael Sporny; Julia Guez-Haddad; Mario Lebendiker; Valeria Ulisse; Allison Volf; Carsten Mim; Michail N Isupov; Yarden Opatowsky
Journal:  J Mol Biol       Date:  2019-07-03       Impact factor: 5.469

5.  NAD+ cleavage activity by animal and plant TIR domains in cell death pathways.

Authors:  Shane Horsefield; Hayden Burdett; Xiaoxiao Zhang; Mohammad K Manik; Yun Shi; Jian Chen; Tiancong Qi; Jonathan Gilley; Jhih-Siang Lai; Maxwell X Rank; Lachlan W Casey; Weixi Gu; Daniel J Ericsson; Gabriel Foley; Robert O Hughes; Todd Bosanac; Mark von Itzstein; John P Rathjen; Jeffrey D Nanson; Mikael Boden; Ian B Dry; Simon J Williams; Brian J Staskawicz; Michael P Coleman; Thomas Ve; Peter N Dodds; Bostjan Kobe
Journal:  Science       Date:  2019-08-23       Impact factor: 47.728

6.  PHENIX: a comprehensive Python-based system for macromolecular structure solution.

Authors:  Paul D Adams; Pavel V Afonine; Gábor Bunkóczi; Vincent B Chen; Ian W Davis; Nathaniel Echols; Jeffrey J Headd; Li-Wei Hung; Gary J Kapral; Ralf W Grosse-Kunstleve; Airlie J McCoy; Nigel W Moriarty; Robert Oeffner; Randy J Read; David C Richardson; Jane S Richardson; Thomas C Terwilliger; Peter H Zwart
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

7.  Structural and Mechanistic Regulation of the Pro-degenerative NAD Hydrolase SARM1.

Authors:  Matthew Bratkowski; Tian Xie; Desiree A Thayer; Shradha Lad; Prakhyat Mathur; Yu-San Yang; Gregory Danko; Thomas C Burdett; Jean Danao; Aaron Cantor; Jennifer A Kozak; Sean P Brown; Xiaochen Bai; Shilpa Sambashivan
Journal:  Cell Rep       Date:  2020-08-04       Impact factor: 9.423

Review 8.  The SARM1 axon degeneration pathway: control of the NAD+ metabolome regulates axon survival in health and disease.

Authors:  Matthew D Figley; Aaron DiAntonio
Journal:  Curr Opin Neurobiol       Date:  2020-04-17       Impact factor: 6.627

9.  SARM1 deficiency promotes rod and cone photoreceptor cell survival in a model of retinal degeneration.

Authors:  Ema Ozaki; Luke Gibbons; Nuno Gb Neto; Paul Kenna; Michael Carty; Marian Humphries; Pete Humphries; Matthew Campbell; Michael Monaghan; Andrew Bowie; Sarah L Doyle
Journal:  Life Sci Alliance       Date:  2020-04-20

Review 10.  Programmed axon degeneration: from mouse to mechanism to medicine.

Authors:  Michael P Coleman; Ahmet Höke
Journal:  Nat Rev Neurosci       Date:  2020-03-09       Impact factor: 34.870

View more
  15 in total

1.  Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection.

Authors:  Yo Sasaki; Jian Zhu; Yun Shi; Weixi Gu; Bostjan Kobe; Thomas Ve; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Exp Neurol       Date:  2021-08-14       Impact factor: 5.330

2.  Neurotoxins subvert the allosteric activation mechanism of SARM1 to induce neuronal loss.

Authors:  Tong Wu; Jian Zhu; Amy Strickland; Kwang Woo Ko; Yo Sasaki; Caitlin B Dingwall; Yurie Yamada; Matthew D Figley; Xianrong Mao; Alicia Neiner; A Joseph Bloom; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Cell Rep       Date:  2021-10-19       Impact factor: 9.423

3.  Divergent signaling requirements of dSARM in injury-induced degeneration and developmental glial phagocytosis.

Authors:  Kelsey A Herrmann; Yizhou Liu; Arnau Llobet-Rosell; Colleen N McLaughlin; Lukas J Neukomm; Jaeda C Coutinho-Budd; Heather T Broihier
Journal:  PLoS Genet       Date:  2022-06-23       Impact factor: 6.020

4.  Distinct developmental and degenerative functions of SARM1 require NAD+ hydrolase activity.

Authors:  E J Brace; Kow Essuman; Xianrong Mao; John Palucki; Yo Sasaki; Jeff Milbrandt; Aaron DiAntonio
Journal:  PLoS Genet       Date:  2022-06-23       Impact factor: 6.020

5.  Enrichment of SARM1 alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders.

Authors:  Jonathan Gilley; Oscar Jackson; Menelaos Pipis; Mehrdad A Estiar; Ammar Al-Chalabi; Matt C Danzi; Kristel R van Eijk; Stephen A Goutman; Matthew B Harms; Henry Houlden; Alfredo Iacoangeli; Julia Kaye; Leandro Lima; John Ravits; Guy A Rouleau; Rebecca Schüle; Jishu Xu; Stephan Züchner; Johnathan Cooper-Knock; Ziv Gan-Or; Mary M Reilly; Michael P Coleman
Journal:  Elife       Date:  2021-11-19       Impact factor: 8.713

6.  SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration.

Authors:  Matthew D Figley; Weixi Gu; Jeffrey D Nanson; Yun Shi; Yo Sasaki; Katie Cunnea; Alpeshkumar K Malde; Xinying Jia; Zhenyao Luo; Forhad K Saikot; Tamim Mosaiab; Veronika Masic; Stephanie Holt; Lauren Hartley-Tassell; Helen Y McGuinness; Mohammad K Manik; Todd Bosanac; Michael J Landsberg; Philip S Kerry; Mehdi Mobli; Robert O Hughes; Jeffrey Milbrandt; Bostjan Kobe; Aaron DiAntonio; Thomas Ve
Journal:  Neuron       Date:  2021-03-02       Impact factor: 17.173

7.  Genetic inactivation of SARM1 axon degeneration pathway improves outcome trajectory after experimental traumatic brain injury based on pathological, radiological, and functional measures.

Authors:  Donald V Bradshaw; Andrew K Knutsen; Alexandru Korotcov; Genevieve M Sullivan; Kryslaine L Radomski; Bernard J Dardzinski; Xiaomei Zi; Dennis P McDaniel; Regina C Armstrong
Journal:  Acta Neuropathol Commun       Date:  2021-05-17       Impact factor: 7.801

Review 8.  A Novel NAD Signaling Mechanism in Axon Degeneration and its Relationship to Innate Immunity.

Authors:  Eleanor L Hopkins; Weixi Gu; Bostjan Kobe; Michael P Coleman
Journal:  Front Mol Biosci       Date:  2021-07-08

Review 9.  Molecular innovations in plant TIR-based immunity signaling.

Authors:  Dmitry Lapin; Oliver Johanndrees; Zhongshou Wu; Xin Li; Jane E Parker
Journal:  Plant Cell       Date:  2022-04-26       Impact factor: 12.085

10.  Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules.

Authors:  Yun Shi; Philip S Kerry; Jeffrey D Nanson; Todd Bosanac; Yo Sasaki; Raul Krauss; Forhad K Saikot; Sarah E Adams; Tamim Mosaiab; Veronika Masic; Xianrong Mao; Faith Rose; Eduardo Vasquez; Marieke Furrer; Katie Cunnea; Andrew Brearley; Weixi Gu; Zhenyao Luo; Lou Brillault; Michael J Landsberg; Aaron DiAntonio; Bostjan Kobe; Jeffrey Milbrandt; Robert O Hughes; Thomas Ve
Journal:  Mol Cell       Date:  2022-03-24       Impact factor: 19.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.